Clinical data
Trade namesCarafen
ATC code
  • None
  • 2-(Diethylamino)ethyl 1-phenylcyclopentanecarboxylate
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.000.922 Edit this at Wikidata
Chemical and physical data
Molar mass289.419 g·mol−1
3D model (JSmol)
  • O=C(OCCN(CC)CC)C2(c1ccccc1)CCCC2
  • InChI=1S/C18H27NO2/c1-3-19(4-2)14-15-21-17(20)18(12-8-9-13-18)16-10-6-5-7-11-16/h5-7,10-11H,3-4,8-9,12-15H2,1-2H3

Caramiphen is an anticholinergic drug used in the treatment of Parkinson's disease.[1] In combination with phenylpropanolamine it is used as a cough suppressant and nasal decongestant to treat symptoms associated with respiratory illnesses such as cold, allergies, hay fever, and sinusitis.[2] It was added to the British National Formulary in 1963, with a dosage of 10 to 20 mg. Side effects include nausea, dizziness, and drowsiness.[3]

It binds to the sigma-1 receptor with an IC50 value of 25 nM.[4]


  1. ^ "Caramiphen". Retrieved 26 September 2012.
  2. ^ "Caramiphen with phenylpropanolamine-oral, Ordrine AT, Rescaps-D, Tuss Vernade, Tusso-Gest". Archived from the original on 29 October 2012. Retrieved 26 September 2012.
  3. ^ BEIRN SF; LAVELLE S (May 2, 1964). "To-day's drugs: Cough suppressants". Br Med J. 1 (5391): 1165–1167. doi:10.1136/bmj.1.5391.1165. PMC 1813498. PMID 14120813.
  4. ^ Klein M, Musacchio JM (October 10, 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–156. doi:10.1007/BF00711241. PMID 3044591. S2CID 33844132.